IL10 and hepatocellular carcinoma: In patients with HCC, defects in the interferon signaling pathway, HCC secret inhibitory molecules (e.g., IL-10, TGF-β), and reduced serum levels of IFNγ are closely linked to more advanced disease stages and worse prognoses [11].